226 related articles for article (PubMed ID: 12678235)
1. Batch potency testing of inactivated erysipelas vaccines by ELISA--development, validation and implementation.
Rosskopf-Streicher U; Johannes S; Gyra H; Beckmann R; Cussler K
Dev Biol (Basel); 2002; 111():153-8. PubMed ID: 12678235
[TBL] [Abstract][Full Text] [Related]
2. Collaborative study for the establishment of erysipelas ELISA coating antigen. European Biological Reference Preparation batch no. 1.
Cussler K; Rosskopf-Streicher U; Volkers P; Milne C
Pharmeuropa Spec Issue Biol; 2001 Aug; 2001(1):75-88. PubMed ID: 11705102
[TBL] [Abstract][Full Text] [Related]
3. Quality assurance of C. perfringens epsilon toxoid vaccines--ELISA versus mouse neutralisation test.
Rosskopf-Streicher U; Volkers P; Noeske K; Werner E
ALTEX; 2004; 21 Suppl 3():65-9. PubMed ID: 15057410
[TBL] [Abstract][Full Text] [Related]
4. Potency Testing of Swine Erysipelas Vaccines by Serology Results of a Pre-validation Study.
Rosskopf-Streicher U; Johannes S; Wilhelm M; Gyra H; Cussler K
ALTEX; 1999; 16(3):123-128. PubMed ID: 11107318
[TBL] [Abstract][Full Text] [Related]
5. [100 years of erysipelas prophylaxis: significance and reduction of animal experiments].
Cussler K; Balks E
ALTEX; 2001; 18(1):29-33. PubMed ID: 11248847
[TBL] [Abstract][Full Text] [Related]
6. General information about the validation of serological method (ELISA) for the batch potency testing erysipelas vaccines.
Altern Lab Anim; 2002; 30(5):486-7. PubMed ID: 12434771
[No Abstract] [Full Text] [Related]
7. Quality control of inactivated erysipelas vaccines: results of an international collaborative study to establish a new regulatory test.
Rosskopf-Streicher U; Johannes S; Wilhelm M; Cussler K
Vaccine; 2001 Jan; 19(11-12):1477-83. PubMed ID: 11163671
[TBL] [Abstract][Full Text] [Related]
8. Potency testing of inactivated erysipelas vaccines by ELISA--influence of the adjuvant on antibody development.
Rosskopf-Streicher U; Johannes S; Cussler K
Dev Biol (Basel); 2002; 111():159-62. PubMed ID: 12678236
[TBL] [Abstract][Full Text] [Related]
9. Towards in vitro potency testing of inactivated erysipelas vaccines.
Balks E; Wolf C; Loessner H; Werner E
Dev Biol (Basel); 2012; 134():37-44. PubMed ID: 22888593
[TBL] [Abstract][Full Text] [Related]
10. Three Rs potential in the development and quality control of immunobiologicals.
Halder M
ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
[TBL] [Abstract][Full Text] [Related]
11. Determination of protective erysipelas antibodies in pig and mouse sera as possible alternatives to the animal challenge models currently used for potency tests.
Beckmann R; Gyra H; Cussler K
Dev Biol Stand; 1996; 86():326. PubMed ID: 8785966
[No Abstract] [Full Text] [Related]
12. Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use.
Winsnes R; Hendriksen C; Sesardic D; Akkermans A; Daas A
Dev Biol Stand; 1999; 101():277-88. PubMed ID: 10566802
[TBL] [Abstract][Full Text] [Related]
13. Potency Testing of Erysipelas Vaccines in Mice. ELISA vs. Challenge.
Beckmann R; Cussler K
ALTEX; 1994; 11(5):39-45. PubMed ID: 11178406
[TBL] [Abstract][Full Text] [Related]
14. Vero cell assay validation of an alternative to the Ph. Eur. diphtheria potency tests.
Gommer AM
Dev Biol Stand; 1996; 86():217-24. PubMed ID: 8785952
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
[TBL] [Abstract][Full Text] [Related]
16. Development of an enzyme-linked immunosorbent assay for the serological detection of exposure of poultry in New Zealand to Erysipelothrix rhusiopathiae and their serological response to vaccination.
Kurian A; Neumann EJ; Hall WF; Christensen N
N Z Vet J; 2012 Mar; 60(2):100-5. PubMed ID: 22352927
[TBL] [Abstract][Full Text] [Related]
17. Investigation about development of alternative efficacy verifications of swine erysipelas vaccines.
Gyra H; Volmer R; Hausleithner D
ALTEX; 1994; 11(5):46-54. PubMed ID: 11178407
[TBL] [Abstract][Full Text] [Related]
18. Development of an enzyme-linked immunosorbent assay for potency testing of erysipelas bacterins.
Henderson LM; Scheevel KF; Walden DM
Dev Biol Stand; 1996; 86():333. PubMed ID: 8785973
[No Abstract] [Full Text] [Related]
19. Prevalence of Met-203 type spaA variant in Erysipelothrix rhusiopathiae isolates and the efficacy of swine erysipelas vaccines in Japan.
Uchiyama M; Yamamoto K; Ochiai M; Yamamoto T; Hirano F; Imamura S; Nagai H; Ohishi K; Horiuchi N; Kijima M
Biologicals; 2014 Mar; 42(2):109-13. PubMed ID: 24405986
[TBL] [Abstract][Full Text] [Related]
20. Veterinary vaccines: In-VITRO--International Veterinary Industry Test Replacement Organisation.
Redhead K; Lucken R; van de Moer A; Houghton S; Simpson B; Cameron A; Monkton P; Hennesy K; Ellis C
Dev Biol Stand; 1999; 101():261-6. PubMed ID: 10566800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
